New Delhi:
Bharat Biotech’s Covaxin is 77.8 per cent efficient in defending in opposition to COVID-19 in response to outcomes of Phase III trial knowledge accepted by the DCGI’s Subject Expert Committee, supply stated this afternoon.
New Delhi:
Bharat Biotech’s Covaxin is 77.8 per cent efficient in defending in opposition to COVID-19 in response to outcomes of Phase III trial knowledge accepted by the DCGI’s Subject Expert Committee, supply stated this afternoon.
